At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
In Brief
A Phase 1 clinical trial evaluating Placebo, RSV sF 20 mcg, and 5 other interventions for Respiratory Syncytial Virus (RSV). Completed, enrolled 246 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine if the administration of single ascending intramuscular doses of the RSV sF antigen or MEDI7510 will be safe and well tolerated in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions.
Study Details
Timeline
Interventions
Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.